Rosemary extracts improve flow‐mediated dilatation of the brachial artery and plasma PAI‐1 activity in healthy young volunteers

Polyphenol antioxidants decrease the risk of atherosclerosis. The study aimed to evaluate prospectively in healthy young participants the effect of oral rosemary extracts (RE), consisting of diphenols, upon endothelial dysfunction (ED), preceding structural atherosclerosis. Nineteen healthy young volunteers were studied prospectively, who received oral RE (77.7 mg) for 21 days, consisting of active substances carnosol (0.97 mg), carnosic (8.60 mg) and rosmarinic acid (10.30 mg). Before and after RE treatment, the study evaluated fasting serum levels of plasminogen‐activator‐inhibitor‐1 (PAI‐1), vascular cell adhesion molecule 1 (VCAM‐1), inter‐cellular adhesion molecule 1 (ICAM‐1), superoxide dismutase (SOD), glutathione peroxidase (GPX), fibrinogen, high‐sensitivity capsular reactive protein (hs‐CRP), tumor‐necrosis factor α (TNF‐α), the lipid profile and ED, characterized as flow‐mediated dilatation (FMD) in the brachial artery of <4.5%, estimated by ultrasound measurements. After 21 days, any side effects were registered, the mean FMD increased nonsignificantly (6.51 ± 5.96% vs 7.78 ± 4.56%, p = 0.546) and ED decreased significantly (66.6% vs 16.6%, p = 0.040). Among the serum markers, only the mean PAI‐1 level decreased significantly (4.25 ± 1.46 U/mL vs 3.0 ± 0.61 U/mL, p = 0.012) after 21‐day RE supplementation. It is concluded that oral RE supplementation has the potential to improve serum PAI‐1 activity and ED in young and healthy individuals. Copyright © 2010 John Wiley & Sons, Ltd.     

Barberry Treatment Reduces Serum Anti‐Heat Shock Protein 27 and 60 Antibody Titres and High‐sensitivity C‐reactive Protein in Patients with Metabolic Syndrome: A Double‐blind,Randomized Placebo‐controlled Trial

Metabolic syndrome is an important risk factor for cardiovascular disease (CVD). The heat shock proteins (HSPs) are associated with risk factors for CVD. The aim of the present study was to survey the effect of barberry on antibody titres to HSPs and high‐sensitivity C‐reactive protein (hs‐CRP) in patients with metabolic syndrome. In our study, subjects (N = 106, 79 women and 27 men, 18–65 years old) with metabolic syndrome were randomized into two groups: a group of patients who received three capsules of barberry and a control group who received three capsules of placebo for 6 weeks. Antibodies against HSPs 27, 60/65 and 70, hs‐CRP and lipid profile were determined in patients before (week 0) and after (week 6) intervention. spss software (version 16.0; Inc, Chicago, IL) was used for data analysis. Results showed that barberry had no significant effect on serum level of anti‐HSPs 65 and 70. But there was a significant decrease in anti‐HSP 27 in both case and control groups (p = 0.001 and p < 0.001, respectively, in the case and control groups). Barberry decreased significantly anti‐HSP 60 in the case group (p = 0.03). High‐sensitivity CRP was decreased non‐significantly (p = 0.17) in the case group and increased significantly (p = 0.04) in the control group. Barberry decreased significantly low‐density lipoprotein and total cholesterol and increased significantly high‐density cholesterol (p < 0.05). Results of the present study suggested that barberry supplementation in patients with metabolic syndrome decreased significantly anti‐HSPs 27 and 60 and hs‐CRP levels and improved lipid profile. Copyright © 2014 John Wiley & Sons, Ltd.     

Effect of turmeric on glycemic status,lipid profile,hs‐CRP,and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients

Diabetes mellitus is the most common metabolic disorder worldwide. This study examined the effect of turmeric supplementation on glycemic status, lipid profile, hs‐CRP and total antioxidant capacity in hyperlipidemic type 2 diabetic patients. In this double‐blind, randomized clinical trial, 80 hyperlipidemic type 2 diabetic patients were divided into turmeric (2,100 mg powdered rhizome of turmeric daily) and placebo groups for 8 weeks. Body weight, fasting plasma glucose, hemoglobin A1c (HbA1c), serum insulin, triglyceride (TG), total cholesterol, low density lypoprotein cholesterol (LDL‐c), high density lypoprotein cholesterol, apolipoprotein A1, apolipoprotein B, high sensitivity C‐reactive protein (hs‐CRP), and total antioxidant capacity were measured before and after intervention. Statistical analysis was carried out using paired and independent t and chi‐square tests. Seventy five patients completed the study. The turmeric group showed significant decreases in body weight, TG, and LDL‐c compared with baseline (p value < 0.05). Body mass index, TG, and total cholesterol decreased significantly in the turmeric group compared with the placebo group (p value < 0.05). No significant changes were observed in other parameters between the two groups after intervention (p value < 0.05). Turmeric improved some fractions of lipid profile and decreased body weight in hyperlipidemic patients with type 2 diabetes. It had no significant effect on glycemic status, hs‐CRP, and total antioxidant capacity in these patients.     

Effect of sour tea supplementation on liver enzymes,lipid profile,blood pressure,and antioxidant status in patients with non‐alcoholic fatty liver disease: A double‐blind randomized controlled clinical trial

The aim of this study was to evaluate the efficacy of sour tea supplementation in patients with nonalcoholic fatty liver disease (NAFLD). Seventy NAFLD patients were enrolled in this randomized, double‐blind, placebo‐controlled clinical trial. Participants received sour tea in the form of a 450 mg capsule or a placebo capsule daily for 8 weeks. Anthropometric indices, liver enzymes, lipid profile, blood pressure, and antioxidant status were evaluated at the baseline and at the end of the study. Sixty‐one participants completed the study. After 8 weeks, sour tea administration significantly decreased serum triglyceride (TG) (p = .03), alanine aminotransferase (ALT) (p = .01), and aspartate aminotransferase (AST) (p = .004) levels compared with the placebo. In addition, sour tea supplementation resulted in a significant reduction in systolic blood pressure (SBP) (p = .03) and diastolic blood pressure (DBP) (p = .04), and a significant increase in serum total antioxidant capacity (TAC) levels (p ? .001) compared with the placebo. However, no significant changes in anthropometric measures, total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐c), and high‐density lipoprotein cholesterol (HDL‐c) levels were observed after sour tea supplementation compared with the placebo (p > .05). Sour tea supplementation may be effective in improving serum TG, liver enzymes, and blood pressure in patients diagnosed with NAFLD. Further studies are needed to address the exact mechanism of action of these effects.     

Inhibitory effect of Thuja orientalis on TNF-α-induced vascular inflammation

Vascular inflammation is involved in the initiation and progression of vascular diseases including atherosclerosis. While conducting in vitro screening of 600 medicinal plant extracts, an aqueous extract of Thuja orientalis (ATO) was found to exhibit antiinflammatory activity in human umbilical vein endothelial cells (HUVEC). In the current study, the antiinflammatory activity of ATO and possible mechanisms for this were investigated in HUVEC. Preincubation with ATO (20 μg/mL) suppressed tumor necrosis factor‐α (TNF‐α)‐induced expression of adhesion molecules including intercellular adhesion molecule‐1 (ICAM‐1), vascular cell adhesion molecule‐1 (VCAM‐1) and E‐selectin at both the protein and mRNA levels. ATO also inhibited U937 monocyte adhesion to HUVEC stimulated by TNF‐α. In addition, ATO attenuated TNF‐α‐induced p65 NF‐κB translocation into the nucleus and phosphorylation of IκB‐α. Furthermore, ATO significantly inhibited TNF‐α‐induced intracellular reactive oxygen species (ROS) production. Overall, the present data suggest that ATO can suppress TNF‐α‐induced vascular inflammatory processes, possibly via inhibition of ROS and NF‐κB activation, in HUVEC. Copyright © 2010 John Wiley & Sons, Ltd.     

Regulation of adhesion molecules expression in TNF‐α‐stimulated brain microvascular endothelial cells by tanshinone IIA: involvement of NF‐κB and ROS generation

Pro‐inflammatory cytokine‐mediated expression of cell surface adhesion molecules plays a key role in endothelial cell injury, leading to vascular inflammation and the development of many cerebrovascular diseases. Thus, antiinflammatory agents targeting these adhesion molecules may represent potential drugs for the prevention and treatment of cerebrovascular diseases. The present study explored the effects of tanshinone IIA (Tan IIA), an active ingredient present in the Salvia miltiorrhiza root, on the expression of cellular adhesion molecules in TNF‐α‐stimulated brain microvascular endothelial cells (BMVECs). Treatment with Tan IIA was found to suppress the expression of vascular cell adhesion molecule‐1 (VCAM‐1) and intercellular adhesion molecule‐1 (ICAM‐1), resulting in inhibition of TNF‐α‐induced adhesion of neutrophils to BMVECs in a dose‐dependent manner. In addition, Tan IIA significantly inhibited TNF‐α‐induced production of reactive oxygen species (ROS), which was accompanied by decreased malondialdehyde (MDA) levels. Treatment with Tan IIA also inhibited nuclear factor‐kappa B (NF‐κB) activation. Together, these results suggest that Tan IIA regulates TNF‐α‐induced expression of VCAM‐1 and ICAM‐1 through inhibition of NF‐κB activation and ROS generation in BMVECs. Copyright © 2010 John Wiley & Sons, Ltd.     

Adjuvant Therapy with Bioavailability‐Boosted Curcuminoids Suppresses Systemic Inflammation and Improves Quality of Life in Patients with Solid Tumors: A Randomized Double‐Blind Placebo‐Controlled Trial

Curcuminoids are bioactive polyphenolics with potent antiinflammatory properties. Although several lines of in vitro and preclinical evidence suggest potent anticancer effects of curcuminoids, clinical findings have not been conclusive. The present randomized double‐blind placebo‐controlled trial aimed to evaluate the efficacy of curcuminoids as adjuvant therapy in cancer patients. Eighty subjects with solid tumors who were under standard chemotherapy regimens were randomly assigned to a bioavailability‐boosted curcuminoids preparation (180 mg/day; n = 40) or matched placebo (n = 40) for a period of 8 weeks. Efficacy measures were changes in the health‐related quality of life (QoL) score (evaluated using the University of Washington index) and serum levels of a panel of mediators implicated in systemic inflammation including interleukins 6 (IL‐6) and 8 (IL‐8), TNF‐α, transforming growth factor‐β (TGFβ), high‐sensitivity C‐reactive protein (hs‐CRP), calcitonin gene‐related peptide (CGRP), substance P and monocyte chemotactic protein‐1 (MCP‐1). Curcuminoid supplementation was associated with a significantly greater improvement in QoL compared with placebo (p < 0.001). Consistently, the magnitude of reductions in TNF‐α (p < 0.001), TGFβ (p < 0.001), IL‐6 (p = 0.061), substance P (p = 0.005), hs‐CRP (p < 0.001), CGRP (p < 0.001) and MCP‐1 (p < 0.001) were all significantly greater in the curcuminoids versus placebo group. In contrast, the extent of reduction in serum IL‐8 was significantly greater with placebo versus curcuminoids (p = 0.012). Quality of life variations were associated with changes in serum TGFβ levels in both correlation and regression analyses. Adjuvant therapy with a bioavailable curcuminoid preparation can significantly improve QoL and suppress systemic inflammation in patients with solid tumors who are under treatment with standard chemotherapy protocols. Copyright © 2014 John Wiley & Sons, Ltd.     

Effects of Supplementation with Curcuminoids on Dyslipidemia in Obese Patients: A Randomized Crossover Trial

Dyslipidemia is a leading risk factor for cardiovascular disease and is also a common feature of obesity. Curcumin is a bioactive phytochemical with well‐known antioxidant, anti‐inflammatory, and cardioprotective properties. The present study investigated the hypolipidemic activity of curcumin in obese individuals. Participants (n = 30) were treated with curcuminoids (1 g/day), or placebo in a randomized, double‐blind, placebo‐controlled, crossover trial. Serum concentrations of total cholesterol, triglycerides, low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol, together with anthropometric parameters and high‐sensitivity C‐reactive protein were measured before and after each treatment period. Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05). As for the lipid profile parameters, serum triglycerides were significantly reduced following curcumin supplementation (p = 0.009). However, curcuminoids were not found to affect serum levels of total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, and high‐sensitivity C‐reactive protein (p > 0.05). In summary, the findings of the present study indicated that curcuminoid supplementation (1 g/day for 30 days) leads to a significant reduction in serum triglycerides concentrations but do not have a significant influence on other lipid profile parameters as well as body mass index and body fat. Copyright © 2012 John Wiley & Sons, Ltd.     

Effect of fenugreek consumption on serum lipid profile: A systematic review and meta‐analysis

Various studies have shown that Trigonella foenum‐graecum (fenugreek) supplementation has lipid‐lowering activity. This meta‐analysis was performed to evaluate the effect of fenugreek supplementation on human serum lipid profile. Data sources were PubMed, EMBASE, Scopus, and Coherence library which were searched systematically from January 2000 up to December 2019. Inclusion criteria were randomized clinical trial (RCT) study design, at least one of lipid profile components (triglyceride [TG], total cholesterol [TC], low‐density lipoprotein cholesterol, and high‐density lipoprotein cholesterol) levels measured before fenugreek use and one of the lipid components level reported as result. The pooled weighted mean difference (MD) and its 95% confidence interval (CI) were calculated and pooled using a random‐effect model. Only articles published in English were considered. Fifteen RCTs involving 281 cases consumed fenugreek and 255 control cases in controlled group (11 articles) and 136 cases in uncontrolled group (4 articles) were analyzed in our study. Pooled data of indicated a significant impact of fenugreek supplementation on lowering TC (?1.13 [?1.88, ?0.37]; p = .003), low‐density lipoprotein (LDL) (?1.26 [?2.09, ?0.43]; p = .003), and TG (?1.07 [?1.82, ?0.33]; p = 0.005) and increasing the high‐density lipoprotein (HDL) level (0.70 [0.07, 1.34]; p = .03) compared with the control group. There were no significant differences in TC, TG, and LDL between pre‐ and post‐fenugreek studies in the noncontrolled studies however, the result of combination of four studies without control group showed a significant increase in mean HDL (0.81 [0.33,1.29]; p‐value = .001). The results of subgroup analysis showed that the fenugreek reduced the TG and LDL and increases HDL levels in diabetic subjects more effectively. Fenugreek supplementation significantly improved lipid profile (LDL, TG, TC, and HDL). It could be considered as an effective lipid‐lowering medicinal plant. Further high‐quality studies are needed to firmly establish the clinical efficacy of the plant.